Onkologie. Reflexionen nach dem 36. „San Antonio Breast Cancer Symposium“ – Was gibt es Neues?

Zum 36. Mal zog es die internationale Gemeinde der Brustkrebsspezialisten in der 2. Dezemberwoche nach San Antonio, Texas. Das „San Antonio Breast Cancer Symposium“ ist inzwischen die wichtigste Konferenz weltweit zu diesem Themengebiet – etwa 8000 Teilnehmer unterstreichen die Bedeutung des Treffens. An den 5 Tagen der Konferenz wurden weit über 1000 wissenschaftliche Abhandlungen präsentiert. Die etwa 80 Wichtigsten hatten die Veranstalter für Vorträge ausgewählt.

Zahlreiche Ergebnisse im Bereich der Basis- sowie translationalen Forschung unterstreichen die Erkenntnis: Das Mammakarzinom als solches gibt es nicht. Vielmehr stellt es einen Oberbegriff für eine Gruppe heterogener Erkrankungen dar – Erkrankungen, denen unterschiedliche genetische Ursachen zugrunde liegen, welche über unterschiedliche pathophysiologische Abläufe zu grundverschiedenen klinischen Verläufen führen.

• Literatur

• 1 Badwe R, Parmar V, Hawaldar R et al. Surgical removal of primary tumor and axillary lymph nodes in women with metastatic breast cancer at first presentation: A randomized controlled trial. SABCS 2013; S2-02.
• 2 Soran A, Ozmen V, Ozbas S et al. Early follow up of a randomized trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer; Turkish study (protocol MF07-01). SABCS 2013; S2-03.
• 3 Kunkler IH, Williams LW, Jack W et al. The PRIME 2 trial: Wide local excision and adjuvant hormonal therapy ± postoperative whole breast irradiation in women ≥ 65 years with early breast cancer managed by breast conservation. SABCS 2013; S2-01.
• 4 Houssami N, Macaskill P, Marinovich ML et al. The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: a meta-analysis. Ann Surg Oncol 2014; 21: 717-730
• 5 Hurvitz S, Miller JM, Dichmann R et al. Final analysis of a phase II 3-arm randomized trial of neoadjuvant trastuzumab or lapatinib or the combination of trastuzumab and lapatinib, followed by six cycles of docetaxel and carboplatin with trastuzumab and/or lapatinib in patients with Her2+ breast cancer (trio-uS B07). SABCS 2013; S1-02.
• 6 Sikov WM, Berry DA, Perou CM et al. Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance). SABCS 2013; S5-01.
• 7 Slamon DJ, Swain SM, Buyse M et al. Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer. SABCS 2013; S1-03.
• 8 Tolaney SM, Barry WT, Dang CT et al. A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). SABCS 2013; S1-04.
• 9 Cognetti F, Bruzzi P, De Placido S et al. Epirubicin and cyclophosphamide (EC) followed by paclitaxel (T) versus fluorouracil, epirubicin and cyclophosphamide (FEC) followed by T, all given every 3 weeks or 2 weeks, in node-positive early breast cancer (BC) patients (pts). Final results of the Gruppo Italiano Mammella (GIM)-2 randomized phase III study. SABCS 2013; S5-06.
• 10 Coleman R, Gnant M, Paterson A et al. Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: A meta-analysis of individual patient data from randomised trials. SABCS 2013; S4-07.
• 11 Mackey JR, Ramos-Vazquez M, Lipatov O et al. Primary results of ROSE/TRIO-12, a randomized placebo controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. SABCS 2013; S5-04.
• 12 Smerage JB, Barlow WE, Hayes DF et al. SWOG S0500 – A randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell (CTC) levels at first follow-up assessment. SABCS 2013; S5-07.
• 13 Cuzick J, Sestak I, Forbes JF et al. First results of the International breast cancer intervention study II (IBIS-II): A multicentre prevention trial of anastrozole versus placebo in postmenopausal women at increased risk of developing breast cancer. SABCS 2013; S3-01.
• 14 Henry NL, Kidwell K, Hayes DF et al. Associations between baseline patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor (AI) therapy. SABCS 2013; S3-02.
• 15 Irwin ML, Cartmel B, Gross C et al. Randomized trial of exercise vs. usual care on aromatase inhibitor-associated arthralgias in women with breast cancer: The hormones and physical exercise (HOPE) study. SABCS 2013; S3-03.